VistaGen Therapeutics Q2 EPS $(0.54) Misses $(0.48) Estimate, Sales $258.000K Beat $243.333K Estimate
Benzinga Newsdesk 12 months ago
EarningsEarnings BeatsEarnings MissesNews
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 13.45 percent. This is a 28.57 percent decrease over losses of $(0.42) per
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 13.45 percent. This is a 28.57 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $258.000 thousand which beat the analyst consensus estimate of $243.333 thousand by 6.03 percent. This is a 40.98 percent increase over sales of $183.000 thousand the same period last year.